SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors weigh strong China market share gains and positive analyst sentiment against broader macroeconomic concerns, including ongoing geopolitical tensions in the Middle East that continue to weigh on the tech sector. The community remains deeply divided, with many debating the impact of upcoming AI product launches and potential supply chain disruptions while expressing frustration over the stock's recent volatility.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as a high-concentration proxy trade for major upcoming IPOs, particularly SpaceX and Anthropic. Investors are actively debating the fund's NAV premium and the potential for a massive price surge driven by pre-IPO hype and the fund's unique position in private tech unicorns.

The Shrimp Army

$SHRIMPS is gaining momentum as part of a broader trend of ocean-themed meme coins circulating on social media. The community is actively debating the coin's potential for rapid gains, with some participants viewing it as a high-risk, short-term play while others express skepticism regarding the long-term viability of the project.

Chess Grandmaster Hans Nieman was accused of cheating during a tournament by wearing a vibrating butt plug which sent morse code for which move he should make. In response dev Ron Sijim created the Buttfish Github.   Buttfish is a github repository which explains how a vibrating butt plug could transmit morse code for chess. In this github he literally says this project is a "meme" so why not make him a memecoin.   He also has a Eth wallet listed for donations, so clearly he is crypto native  Send Buttfish Coin

Buttfish Coin

Buttfish Coin is gaining traction as a viral meme asset, with the community actively debating its speculative nature and speculative surge within the broader sea-themed crypto sector.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is capturing investor attention as the community anticipates a significant breakout, with many bulls actively loading up on dips while speculating on long-term utility in the Web3 gaming and AI sectors. Traders are closely monitoring technical support levels and volume patterns, with much of the discussion focused on the potential for a rally despite recent market volatility.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure amid broader market uncertainty, compounded by a legal setback in a social media harm lawsuit and growing investor anxiety over massive capital expenditures in AI. The community is actively debating the company's valuation, questioning its heavy spending on the Reality Labs division, and speculating on the potential for upcoming layoffs to improve operational efficiency.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is currently facing intense selling pressure as investors grapple with lingering fallout from a short-seller report and broad macroeconomic uncertainty, including geopolitical tensions. While some shareholders remain focused on long-term growth and potential product catalysts, the community is deeply divided, with many expressing frustration over persistent price declines, management's lack of public response to allegations, and ongoing concerns about potential dilution.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is generating significant buzz following an insider-led buying spree and the anticipation of institutional accumulation, fueling community speculation about a potential short squeeze. Investors are closely monitoring the impact of the company's AI-driven 'Tinman' platform and key strategic partnerships on its market positioning as it seeks to scale its digital mortgage business.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is currently seeing significant community interest driven by recent progress in well drilling at the Renergen project, coupled with intensifying supply constraints for helium and LNG following regional geopolitical tensions. Investors are actively discussing the firm's role in the HALEU and isotope supply chain, closely monitoring technical updates regarding production scaling and awaiting potential breakthroughs in Silicon-28 commercialization.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco Wholesale is currently trending as investors focus on its resilient growth, high membership renewal rates, and expansion into new product categories like energy drinks. The community is actively debating the company's premium valuation compared to traditional retail peers, alongside recent news about standalone gas stations and potential tariff-related litigation impacts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Equity

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

<ul class="summary-bullets"><li>The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.</li><li>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients.</li><li>The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of self-harm among GLP-1 users versus patients taking other diabetes drugs.</li></ul>The U.S. Food and Drug Administration (FDA) on Tuesday asked drugmakers to remove warnings about suicidal thoughts and behavior from the labels of certain popular weight-loss medications after finding no evidence of increased risk.The request applies to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for obesity, including Novo Nordisk’s (NVO) Wegovy and Saxenda, and Eli Lilly’s (LLY) Zepbound.The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.These warnings were originally included as a precaution, based largely on reports tied to older weight-loss drugs rather than GLP-1 therapies specifically. Notably, GLP-1 medications approved for type 2 diabetes have never carried such warnings, and the FDA said the change will ensure consistent labeling across the drug class.<h2 class="st-heading-2">FDA’s Analysis</h2>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients. The analysis found no increased risk of suicidal thoughts, self-injurious behavior (SI/B), or other psychiatric adverse events such as depression or anxiety.The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of intentional self-harm among GLP-1 users compared with patients taking other diabetes drugs.The findings reaffirm results from a preliminary FDA review released in early 2024 and align with conclusions from a separate UK review in the same year. The Medicines and Healthcare products Regulatory Agency (MHRA) had found no evidence linking weight-loss and diabetes drugs to suicides or suicidal thoughts.At the time of writing, <a href="https://stocktwits.com/symbol/LLY">LLY</a> and <a href="https://stocktwits.com/symbol/NVO">NVO</a> stocks were trading 0.1% and 0.2% lower, respectively. Retail sentiment for both stocks was in the ‘bullish’ territory.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-bctx-stock-surge-50-today/cmUX95vR4Ic">Why Did BCTX Stock Surge 90% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings

The request applies to GLP-1 RAs approved for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound.

LLYX
Defiance Daily Target 2X Long LLY ETF

Feed

News

Sentiment

Fundamentals

Info

Latest LLYX News

LLYXDefiance Daily Target 2X Long LLY ETF